Medication Description: Lenograstim
Synonym: Granocyte, Granocyte.
Glycoprotein containing 174 amino acid residues.
Obtained by genetic engineering by expressing a human granulocyte colony-stimulating factor.
Stimulates leukopoesis, accelerating the differentiation of bone marrow cells and increasing the number of full neutrophils emerging from it.
Indications for use, precautions, possible side effects and contraindications are basically the same as those of other colony-stimulating factors.
The recommended dose is 150 μg (19 200 000 IU) per 1 m 2 of body surface per day. During chemotherapy of oncological diseases, lenograstim is injected under the skin, starting from the day after the end of the course of chemotherapy. Treatment continues until normalization of neutrophils in the peripheral blood. For bone marrow transplantation, they are administered intravenously (within 30 minutes), starting from the day after the operation, daily until neutrophil levels stabilize.
Product form: lyophilized powder for injection solutions in vials of 13,400,000, 33,600,000 and 47,000,000 IU, complete with solvent.
For subcutaneous administration, the contents of the vial are diluted ex tempore in the attached solvent. For intravenous infusions, the contents of the vial are first dissolved in the supplied water for injection, then diluted in 0.9% (isotonic) sodium chloride solution: 13,400,000 IU in 50 ml; 33 600 000 IU - in 100 ml; 47 million IU - 140 ml.
Storage: at temperature from +2 to +8 ° С.